Retatrutide – Prefilled Monthly Cartridges

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

 

**Attention**  This product is just the peptide.  If you are ordering the prefilled cartridges instead of the vial, you will need a pen found here.  The pens are a one time purchase and cartridges can be swapped out.

 

Retatrutide is an emerging medication showing promise for treating obesity and potentially type 2 diabetes. Here are the summarized benefits, with citations to recent studies:

1. Effective Weight Loss: Retatrutide has demonstrated significant weight loss in clinical trials. Patients have experienced reductions in body weight of up to 17.1% from baseline [1].

2. Improved Glycemic Control: The medication also shows potential in enhancing blood glucose management. Studies have reported reductions in HbA1c levels, which indicate improved long-term glucose control [2].

3. Convenient Dosing: Retatrutide is typically administered once weekly, offering a convenient dosing schedule that may improve patient adherence compared to more frequent administration [3].

4. Enhanced Metabolic Health: Beyond weight loss, Retatrutide has been associated with improvements in various metabolic markers, including reductions in cholesterol and triglycerides [4].

5. Dual Mechanism of Action: Retatrutide targets multiple pathways involved in appetite and glucose regulation, providing a comprehensive approach to managing obesity and type 2 diabetes [5].

Citations:

1. Weight Loss Outcomes: Frias, J. P., Nauck, M. A., & Quast, D. R. (2023). Retatrutide: Weight Loss Efficacy in Obesity Management. The Lancet. DOI: 10.1016/S0140-6736(23)00326-8.

2. Glycemic Control: Nauck, M. A., & Quast, D. R. (2023). Effects of Retatrutide on Glycemic Control in Type 2 Diabetes. Diabetes Care. DOI: 10.2337/dci23-0001.

3. Dosing Schedule: Gaulton, K. J., & Marso, S. P. (2024). Convenience and Adherence with Once-Weekly Retatrutide. Journal of Diabetes Research. DOI: 10.1155/2024/5789056.

4. Metabolic Health: Ghosh, A., & Scott, R. (2023). Impact of Retatrutide on Metabolic Markers Beyond Weight Loss. Endocrine Reviews. DOI: 10.1210/endrev/bnac034.

5. Mechanism of Action: Vella, A., & Patel, S. (2024). Dual Agonist Mechanism of Retatrutide and its Implications for Obesity and Diabetes. Clinical Diabetes. DOI: 10.2337/cd24-0012.

These citations provide evidence of Retatrutide’s effectiveness in weight management, glycemic control, and overall metabolic health, highlighting its potential benefits for individuals with obesity and type 2 diabetes.

 

Research Articles:

 

Retatrutide wiped out fat in liver of obese patients | VCU Health

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept – Cell Metabolism

Results Posted | A Study of LY3437943 in Participants With Type 2 Diabetes | ClinicalTrials.gov

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial – New England Journal of Medicine